What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
Jordi Bruix mostly deals with Hepatocellular carcinoma, Internal medicine, Surgery, Carcinoma and Sorafenib.
Jordi Bruix studies Liver cancer which is a part of Hepatocellular carcinoma.
His biological study spans a wide range of topics, including Gastroenterology and Oncology.
The study incorporates disciplines such as Recurrent Hepatocellular Carcinoma, Placebo-controlled study and Doxorubicin in addition to Gastroenterology.
His work on Clinical endpoint, Intention-to-treat analysis and Adjuvant therapy as part of general Surgery research is frequently linked to Standard treatment, bridging the gap between disciplines.
His work deals with themes such as Stage, Cancer, Percutaneous ethanol injection and Survival rate, which intersect with Carcinoma.
His most cited work include:
- Sorafenib in Advanced Hepatocellular Carcinoma (7596 citations)
- Management of hepatocellular carcinoma: An update (6093 citations)
- Management of hepatocellular carcinoma. (4880 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Hepatocellular carcinoma, Internal medicine, Oncology, Gastroenterology and Sorafenib.
His Hepatocellular carcinoma study incorporates themes from Radiology, Cirrhosis, Carcinoma and Surgery.
His work on Liver transplantation, Regorafenib, Adverse effect and Liver function as part of general Internal medicine research is often related to In patient, thus linking different fields of science.
His Oncology research is mostly focused on the topic Overall survival.
His study ties his expertise on Hepatitis C together with the subject of Gastroenterology.
The concepts of his Sorafenib study are interwoven with issues in Clinical trial and Hazard ratio.
He most often published in these fields:
- Hepatocellular carcinoma (67.37%)
- Internal medicine (58.30%)
- Oncology (30.50%)
What were the highlights of his more recent work (between 2015-2021)?
- Hepatocellular carcinoma (67.37%)
- Internal medicine (58.30%)
- Oncology (30.50%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Hepatocellular carcinoma, Internal medicine, Oncology, Sorafenib and Regorafenib.
His Hepatocellular carcinoma study integrates concerns from other disciplines, such as Cirrhosis, Carcinoma, Hepatitis C and Clinical trial.
The various areas that Jordi Bruix examines in his Internal medicine study include Gastroenterology and Surgery.
Jordi Bruix combines subjects such as Liver transplantation, Incidence and General surgery with his study of Gastroenterology.
Jordi Bruix has researched Oncology in several fields, including Sorafenib treatment, Tumor progression, Nivolumab and Lenvatinib.
His studies deal with areas such as Liver cancer, Liver function, Proportional hazards model and Hazard ratio as well as Sorafenib.
Between 2015 and 2021, his most popular works were:
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial (1397 citations)
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. (789 citations)
- Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy (611 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
His primary scientific interests are in Hepatocellular carcinoma, Internal medicine, Oncology, Sorafenib and Surgery.
His work in the fields of Hepatocellular carcinoma, such as Liver cancer, intersects with other areas such as In patient.
Many of his studies involve connections with topics such as Gastroenterology and Internal medicine.
His Oncology research incorporates themes from Response rate, Proportional hazards model, Treatment efficacy and Durvalumab.
His Sorafenib research incorporates elements of Regorafenib, Adverse effect and Hazard ratio.
Jordi Bruix focuses mostly in the field of Surgery, narrowing it down to matters related to Carcinoma and, in some cases, Retrospective cohort study, RNA and Gene expression.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
